Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Pharmacology|April 6, 2022
Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus ErythematosusJoachim Almquist, Denison Kuruvilla, Tu Mai, et al.Journal of Clinical Pharmacology|March 30, 2022
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus ErythematosusYen Lin Chia, Raj Tummala, Tu H Mai, et al.The Lancet. Rheumatology|January 27, 2024
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyIan N Bruce, Alireza Nami, Erik Schwetje, et al.Annals of the Rheumatic Diseases|February 11, 2022
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritisDavid Jayne, Brad Rovin, Eduardo F Mysler, et al.British Journal of Clinical Pharmacology|February 21, 2020
Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemiaDenison Kuruvilla, Yen Lin Chia, Kemal Balic, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin LymphomaZufei Zhang, Daping Zhang, Wenchuan Guo, et al.British Journal of Clinical Pharmacology|December 1, 2022
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearanceMichael Hwang, Yen Lin Chia, Yanan Zheng, et al.Drug Design, Development and Therapy|February 2, 2023
Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese ParticipantsTommy Tsang Cheung, Tu H Mai, Yen Lin Chia, et al.The Lancet. Oncology|October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 studyAhmad Awada, Agustin A Garcia, Stephen Chan, et al.Pageof 2